Company Filing History:
4 out of 29 
2 out of 112 Years Active: 1992-2000
Title: The Innovative Contributions of Reinhard Muckenschnabel
Introduction
Reinhard Muckenschnabel, based in Frankfurt-am-Main, Germany, is a renowned inventor with a significant impact on the pharmaceutical sector. With six patents to his name, his contributions to the field have focused on enhancing the solubility of azelastine, a compound used in various therapeutic applications.
Latest Patents
Muckenschnabel’s latest innovations include two notable patents concerning salts of azelastine. The first invention details salts of azelastine that demonstrate improved solubility, which are effective at treating certain conditions. The second patent describes the preparation of these salts through the reaction of azelastine with acetic acid, gluconic acid, lactic acid, or malic acid. This innovation aims to provide a cytoprotective effect, significantly improving the therapeutic potential of azelastine in medical applications.
Career Highlights
Over the course of his career, Reinhard Muckenschnabel has worked with notable companies in the pharmaceutical industry, including Asta Pharma and Asta Medica. His expertise and dedication to research have allowed him to spearhead advancements in medication formulation, thereby improving patient outcomes.
Collaborations
Throughout his journey as an inventor, Muckenschnabel has collaborated with esteemed colleagues such as Helmut Hettche and Gerhard Scheffler. These partnerships have fostered a collaborative environment that encourages innovation and the development of cutting-edge solutions in the field.
Conclusion
Reinhard Muckenschnabel’s contributions to the field of pharmaceuticals through his innovative patents signify a commitment to enhancing medical treatments. His work on azelastine salts not only showcases his inventive prowess but also highlights the importance of collaboration in driving advancements in healthcare solutions. As he continues to inspire future generations of inventors, his legacy remains an essential part of the ongoing evolution in pharmaceutical research.